Randomised phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)


Session type:

Marc Peeters1, Tim Price2, Yevhen Hotko3, Andres Cervantes4, Michel Ducreux5, Thierry Andr6, Emily Chan7, Florian Lordick8, Alan Rong9, Jennifer Gansert9

1University Hospital Ghent, Belgium, 2Queen Elizabeth Hospital, Woodville, Australia, 3Uzhgorod National University, Ukraine, 4Hospital Clinico Universitario, Valencia, Spain, 5Institut Gustave Roussy, Villejuif, France, 6Hpital Piti-Salptrire, Paris, France, 7Vanderbilt University Medical Center, Tennessee, USA, 8Nationales Centrum fr Tumourerkrankungen, Heidelberg, Germany, 9Amgen Inc, California, USA


Panitumumab (pmab) is a fully human anti‑epidermal growth factor receptor monoclonal antibody approved as monotherapy for pts with mCRC.